Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.

ABSTRACT:

Background

Proprotein convertase subtilisin/kexin 9 (PCSK9) is an important regulator of low-density lipoprotein receptor (LDLR) and plasma levels of LDL cholesterol (LDL-C). PCSK9 inhibition is an efficient therapeutic approach for the treatment of dyslipidemia. We tested the therapeutic effect of a PCSK9 vaccine on dyslipidemia and atherosclerosis.

Methods

Lipid film hydration method was used to prepare negatively charged nanoliposomes as a vaccine delivery system. An immunogenic peptide called immunogenic fused PCSK9-tetanus (IFPT) was incorporated on the surface of nanoliposomes using DSPE-PEG-maleimide lipid (L-IFPT) and adsorbed to Alhydrogel® (L-IFPTA⁺). The prepared vaccine formulation (L-IFPTA⁺) and empty liposomes (negative control) were inocu

SUBMITTER: Momtazi-Borojeni AA 

PROVIDER: S-EPMC6902459 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature